Jill Durocher

Mifepristone–Misoprostol for Menstrual Regulation in Public Sector Facilities in Bangladesh

February 14th, 2018
Medication Abortion
Alam, A., Lotarevich, T., Das, T.R., Reichenbach, L., Bracken, H.

Int J Gynecology & Obstetrics; 2018 Feb 14; Vol. 140(2):205-210; doi:10.1002/ijgo.12356

Objective: To examine the use of mifepristone and misoprostol for menstrual regulation among Bangladeshi women attending public sector facilities.

Methods: In a prospective study, women (aged ≥18 years) with up to 9 weeks of amenorrhea were enrolled at 24 government health facilities in Bangladesh from November 2012 to June 2015. Paramedics or female welfare visitors provided most menstrual regulation care. Participants took 200 mg mifepristone followed by 800 μg buccal misoprostol after 24 hours, and were asked to return to the clinic 10–14 days later for clinical assessment and an exit interview. The primary outcome was successful evacuation of the uterus without need for surgical intervention. Women who completed follow-up were included in analyses for the primary outcome.

Results: Among 1744 enrolled participants, 1738 completed follow-up. Most (1674, 96.3%) had a successful uterine evacuation without the need for surgical intervention. A successful outcome was significantly more common in primary (724/744, 97.3%) and secondary facilities (861/895, 96.2%) than in the specialty hospital (89/99, 89.9%; P<0.001 and P=0.004, respectively).

Conclusion: Menstrual regulation with mifepristone and misoprostol can be provided effectively in public sector facilities in Bangladesh.